Enjoy complimentary customisation on priority with our Enterprise License!
According to Technavio's analyst, the human vaccine market size is expected to be valued at USD 20.37 billion by 2026 at a progressing CAGR of 7.73%. One of the key highlights of the human vaccine market research report is the post COVID-19 impact analysis on the market, which will help companies evaluate their business approaches for the forecast period. The human vaccine market report offers information on several market vendors, including Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi, and Serum Institute of India Pvt. Ltd. among others. Furthermore, the human vaccine market has been broadly categorized into the following demographic segmentations:
Download the Free Report Sample to Unlock the Human Vaccine Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The increase in investments in the vaccines segment is notably driving the human vaccine market growth, although factors such as concerns about the safety of vaccines may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the human vaccine industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Human Vaccine Market Driver
Such increasing investments will drive the human vaccine market growth during the forecast period.
Key Human Vaccine Market Trend
Key Human Vaccine Market Challenge
This human vaccine market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global human vaccine market as a part of the global pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the human vaccine market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the human vaccine market encompasses successful business strategies deployed by the key vendors. The human vaccine market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The human vaccine market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the human vaccine market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the human vaccine market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The increasing number of immunization programs and strong prevalence of infectious diseases will facilitate the human vaccine market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 had a positive impact on the regional market. However, by 2023, it is expected that a large proportion of the population will be vaccinated against COVID-19 in North America. Therefore, the market growth of the COVID-19 vaccine might decline in the region during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The human vaccine market share growth by the intramuscular segment will be significant during the forecast period. The intramuscular segment is expected to witness accelerated growth during the forecast period. One of the main reasons for this growth is the benefits of intramuscular administration. It is efficient and safe in inducing an immune response compared with the oral ROA. Many pipeline vaccine products are being evaluated in the intramuscular ROA because of their advantages over the oral ROA. Thus, the market has witnessed the development and approval of an intramuscular vaccine for COVID-19, which is expected to drive the growth of the segment during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the human vaccine market size and actionable market insights on post COVID-19 impact on each segment.
|
Human Vaccine Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.73% |
|
Market growth 2022-2026 |
$ 20.37 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
5.3 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 38% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi, and Serum Institute of India Pvt. Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Route of Administration
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
